PTCT 241220 47.00P (PTCT241220P47000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PTCT241220P47000

Watchlist

1.54
0.000.00%

15min DelayClose Dec 12 16:00 ET

1.54High1.54Low

Intraday

5D
Daily

News

Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $67
Moomoo News20:32 ET · Ratings
PTC Therapeutics Upgraded to Overweight From Equal Weight at Morgan Stanley
TipRanks20:15 ET
Raymond James, Cantor Bullish on UniQure Following FDA Update
Seeking AlphaDec 10 13:11 ET
Cantor Fitzgerald Says 'Aggressively' Buy UniQure, PTC Therapeutics
TipRanksDec 10 07:55 ET
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
BenzingaDec 6 13:10 ET
PTC Therapeutics: Hold Rating Amid Strategic Collaboration With Novartis and Clinical Uncertainties
TipRanksDec 6 00:55 ET · Ratings

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Moomoo AI

Nov 18, 2023 08:43

PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.

PTC Therapeutics (NASDAQ:PTCT) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 68%